Medical Therapy for Kidney Stones

How to cite: Madore, L. “Medical Therapy for Kidney Stones.” December 3, 2025. Accessed Mar 2026. https://grandroundsinurology.com/medical-therapy-for-kidney-stones/

Summary

Diane K. Newman, DNP, ANP-BC, FAAN, FAUNA, BCB-PMD, Senior Editorial Director, Grand Rounds in Urology, and Urology and Pelvic Floor Nurse Specialist, University of Pennsylvania, Philadelphia, Pennsylvania, Adjunct Professor of Surgery, Division of Urology, Perelman School of Medicine, Emerita, introduces Les Madore, MS, PA-C, Sandy, Utah. PA Madore presents a structured approach to the medical management of kidney stones.

PA Madore emphasizes that patients with more than one stone, a large stone, or a high stone risk receive a comprehensive metabolic evaluation that includes a 48-hour urine collection, serum studies, urinalysis, and stone analysis when available. Key laboratory elements are parathyroid hormone, uric acid, vitamin D, phosphorus, a basic metabolic panel, and measures of kidney function. The medical and dietary history explores calcium supplements, vitamin D use, calcium-rich food intake, animal-based protein consumption, sodium sources, fluid habits, bowel disease, malabsorption, diabetes mellitus, gout, sarcoidosis, renal tubular acidosis, bone disorders, and family history of kidney stones.

Dietary guidance targets a daily urine output of two to three liters, a sodium intake of approximately 1,200 to 2,300 milligrams, a normal dietary calcium intake for bone health, a restriction of animal protein to roughly six to eight ounces, and a limitation of high-oxalate foods while maintaining a balanced intake of fruits and vegetables. PA Madore explains 24 hour urine samples represent a snapshot and must be interpreted in consideration of bowel function and recent diet. He reviews how abnormalities in calcium, oxalate, citrate, pH, uric acid, sodium, potassium, magnesium, phosphorus, ammonia, and creatinine point to issues such as hypercalciuria, hyperoxaluria, low citrate states, high animal protein intake, infection, malabsorption, or incomplete urine collections.

Pharmacologic prevention includes thiazide diuretics for hypercalciuria, potassium citrate for low citrate or acidic urine in patients with calcium, uric acid, or cystine stone formers, and the selective use of allopurinol in patients with elevated uric acid and recurrent calcium oxalate stones with normal urine calcium levels. Cystine-binding agents are reserved for cystinuria with a significant stone burden, and acetohydroxamic acid is used in patients with recurrent struvite stones after surgical management. 

The presentation includes a Q&A session with Dr. Newman and PA Madore.